iTeos Therapeutics, Inc.

10.74 USD
-0.53 (-4.70%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

iTeos Therapeutics, Inc. stock is up 7.83% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 March’s closed higher than February. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Feb 14:32 19 Apr, 2024 10.00 CALL 246 14

About iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc. engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials. EOS-448 is an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains.